These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27077499)

  • 1. Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery.
    Oliveira PA; Gil da Costa RM; Vasconcelos-Nóbrega C; Arantes-Rodrigues R; Pinto-Leite R
    Expert Opin Drug Discov; 2016 Jun; 11(6):599-607. PubMed ID: 27077499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of urinary bladder cancer and their application to novel drug discovery.
    Oliveira PA; Arantes-Rodrigues R; Vasconcelos-Nóbrega C
    Expert Opin Drug Discov; 2014 May; 9(5):485-503. PubMed ID: 24670247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer.
    Arantes-Rodrigues R; Colaço A; Pinto-Leite R; Oliveira PA
    Anticancer Res; 2013 Apr; 33(4):1273-96. PubMed ID: 23564765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
    Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
    Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and therapeutic applications of the molecular events in clinical management of urothelial carcinoma of bladder.
    Garg M
    J Exp Ther Oncol; 2014; 10(4):301-16. PubMed ID: 25509986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder cancer: molecular determinants of personalized therapy.
    Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
    Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
    Xiao Z; Mak A; Koch K; Moore RB
    BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer drug discovery: recent innovative approaches to tumor modeling.
    Lovitt CJ; Shelper TB; Avery VM
    Expert Opin Drug Discov; 2016 Sep; 11(9):885-94. PubMed ID: 27454169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Big data' approaches for novel anti-cancer drug discovery.
    Benstead-Hume G; Wooller SK; Pearl FMG
    Expert Opin Drug Discov; 2017 Jun; 12(6):599-609. PubMed ID: 28462602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.
    Garg M
    Cancer Metastasis Rev; 2015 Dec; 34(4):691-701. PubMed ID: 26328525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer benefits of early versus late use of rapamycin in a rat model of urothelial carcinoma.
    Chang CH; Fu YC; Li JR; Shu KH; Ho HC; Shiu YN; Wu MJ
    Transplant Proc; 2014 May; 46(4):1240-2. PubMed ID: 24815170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent.
    Ojha R; Singh SK; Bhattacharyya S; Dhanda RS; Rakha A; Mandal AK; Jha V
    J Urol; 2014 Jun; 191(6):1889-98. PubMed ID: 24440234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to improve drug delivery in bladder cancer therapy.
    Wirth M; Plattner VE; Gabor F
    Expert Opin Drug Deliv; 2009 Jul; 6(7):727-44. PubMed ID: 19538035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
    Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
    Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
    Bambury RM; Benjamin DJ; Chaim JL; Zabor EC; Sullivan J; Garcia-Grossman IR; Regazzi AM; Ostrovnaya I; Apollo A; Xiao H; Voss MH; Iyer G; Bajorin DF; Rosenberg JE
    Oncologist; 2015 May; 20(5):508-15. PubMed ID: 25845990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic challenges in advanced bladder cancer.
    Bellmunt J; Petrylak DP
    Semin Oncol; 2012 Oct; 39(5):598-607. PubMed ID: 23040256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.